Search

Your search keyword '"Marumo, Yoshiaki"' showing total 26 results
Start Over Author "Marumo, Yoshiaki"
26 results on '"Marumo, Yoshiaki"'

2. Clinical Significance of Cytomegalovirus Reactivation in Patients With Plasma Cell Dyscrasia Who Were Treated With Anti-CD38 Monoclonal Antibody: A Retrospective Analysis in a Single Institution

Author

Matsunaga, Naohiro, Suzuki, Tomotaka, Nishitarumizu, Nozomi, Nakanishi, Yoko, Kondo, Aki, Kato, Yukiyasu, Ebina, Toru, Marumo, Yoshiaki, Nakamura, Tomoyuki, Nakashima, Takahiro, Kinoshita, Shiori, Narita, Tomoko, Ri, Masaki, Kusumoto, Shigeru, Komatsu, Hirokazu, and Iida, Shinsuke

Published
2024
Full Text
View/download PDF

3. A comprehensive evaluation of humoral immune response to second and third SARS-CoV-2 mRNA vaccination in patients with malignant lymphoma

Author

Suzuki, Tomotaka, Kusumoto, Shigeru, Kamezaki, Yoshiko, Hashimoto, Hiroya, Nishitarumizu, Nozomi, Nakanishi, Yoko, Kato, Yukiyasu, Kawai, Akimi, Matsunaga, Naohiro, Ebina, Toru, Nakamura, Tomoyuki, Marumo, Yoshiaki, Oiwa, Kana, Kinoshita, Shiori, Narita, Tomoko, Ito, Asahi, Inagaki, Atsushi, Ri, Masaki, Komatsu, Hirokazu, Aritsu, Takashi, and Iida, Shinsuke

Published
2023
Full Text
View/download PDF

5. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome.

Author

Maeda, Ayaka, Tsuchida, Naomi, Uchiyama, Yuri, Horita, Nobuyuki, Kobayashi, Satoshi, Kishimoto, Mitsumasa, Kobayashi, Daisuke, Matsumoto, Haruki, Asano, Tomoyuki, Migita, Kiyoshi, Kato, Ayaka, Mori, Ichiro, Morita, Hiroyuki, Matsubara, Akihiro, Marumo, Yoshiaki, Ito, Yuji, Machiyama, Tomoaki, Shirai, Tsuyoshi, Ishii, Tomonori, and Kishibe, Mari

Subjects
RISK assessment, RECEIVER operating characteristic curves, RESEARCH funding, POLYMERASE chain reaction, AUTOINFLAMMATORY diseases, ENZYMES, DESCRIPTIVE statistics, GENETIC variation, CYTOPLASM, LUNG diseases, X-linked genetic disorders, GENETIC mutation, MACROCYTIC anemia, GENETIC testing, SEQUENCE analysis, GENETICS, ALLELES
Abstract

Objectives To efficiently detect somatic UBA1 variants and establish a clinical scoring system predicting patients with pathogenic variants in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. Methods Eighty-nine Japanese patients with clinically suspected VEXAS syndrome were recruited [81 males and 8 females; median age of onset 69.3 years (interquartile range 62.1–77.6)]. Peptide nucleic acid–clamping PCR (PNA-PCR), regular PCR targeting exon 3 clustering UBA1 variants and subsequent Sanger sequencing were conducted for variant screening. Partitioning digital PCR or targeted amplicon deep sequencing was also performed to evaluate the variant allele frequency (VAF). We developed our clinical scoring system to predict UBA1 variant-positive and -negative patients and assessed the diagnostic value of our system using receiver operating characteristics (ROC) curve analysis. Results Forty patients (44.9%) with reported pathogenic UBA1 variants were identified, including a case having a variant with VAF of 1.7%, using a highly sensitive method. Our clinical scoring system considering age >50 years, cutaneous lesions, lung involvement, chondritis and macrocytic anaemia efficiently predicted patients with UBA1 variants (the area under the curve for the scoring total was 0.908). Conclusion Genetic screening with the combination of regular PCR and PNA-PCR detected somatic UBA1 variants with high sensitivity and specificity. Our scoring system could efficiently predict patients with UBA1 variants. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome

Author

Maeda, Ayaka, primary, Tsuchida, Naomi, additional, Uchiyama, Yuri, additional, Horita, Nobuyuki, additional, Kobayashi, Satoshi, additional, Kishimoto, Mitsumasa, additional, Kobayashi, Daisuke, additional, Matsumoto, Haruki, additional, Asano, Tomoyuki, additional, Migita, Kiyoshi, additional, Kato, Ayaka, additional, Mori, Ichiro, additional, Morita, Hiroyuki, additional, Matsubara, Akihiro, additional, Marumo, Yoshiaki, additional, Ito, Yuji, additional, Machiyama, Tomoaki, additional, Shirai, Tsuyoshi, additional, Ishii, Tomonori, additional, Kishibe, Mari, additional, Yoshida, Yusuke, additional, Hirata, Shintaro, additional, Akao, Satoshi, additional, Higuchi, Akitsu, additional, Rokutanda, Ryo, additional, Nagahata, Ken, additional, Takahashi, Hiroki, additional, Katsuo, Koske, additional, Ohtani, Toshio, additional, Fujiwara, Hiroshi, additional, Nagano, Hiromichi, additional, Hosokawa, Takashi, additional, Ito, Takanori, additional, Haji, Yoichiro, additional, Yamaguchi, Hiroyuki, additional, Hagino, Noboru, additional, Shimizu, Toshimasa, additional, Koga, Tomohiro, additional, Kawakami, Atsushi, additional, Kageyama, Goichi, additional, Kobayashi, Hiroshi, additional, Aoki, Akiko, additional, Mizokami, Akinari, additional, Takeuchi, Yoichi, additional, Motohashi, Rena, additional, Hagiyama, Hiroyuki, additional, Itagane, Masaki, additional, Teruya, Hiroyuki, additional, Kato, Tomohiro, additional, Miyoshi, Yuji, additional, Kise, Takayasu, additional, Yokogawa, Naoto, additional, Ishida, Takako, additional, Umeda, Naoki, additional, Isogai, Shuntaro, additional, Naniwa, Taio, additional, Yamabe, Toru, additional, Uchino, Kaori, additional, Kanasugi, Jo, additional, Takami, Akiyoshi, additional, Kondo, Yasushi, additional, Furuhashi, Kazunori, additional, Saito, Koichi, additional, Ohno, Shigeru, additional, Kishimoto, Daiga, additional, Yamamoto, Mari, additional, Fujita, Yoshiro, additional, Fujieda, Yuichiro, additional, Araki, Sachiko, additional, Tsushima, Hiroshi, additional, Misawa, Kyohei, additional, Katagiri, Akira, additional, Kobayashi, Takahiro, additional, Hashimoto, Kenichi, additional, Sone, Takehiro, additional, Hidaka, Yukiko, additional, Ida, Hiroaki, additional, Nishikomori, Ryuta, additional, Doi, Hiroshi, additional, Fujimaki, Katsumichi, additional, Akasaka, Keiichi, additional, Amano, Masako, additional, Matsushima, Hidekazu, additional, Kashino, Kaori, additional, Ohnishi, Hidenori, additional, Miwa, Yuki, additional, Takahashi, Noriyuki, additional, Takase-Minegishi, Kaoru, additional, Yoshimi, Ryusuke, additional, Kirino, Yohei, additional, Nakajima, Hideaki, additional, and Matsumoto, Naomichi, additional

Published
2023
Full Text
View/download PDF

10. P820: POTENTIAL IMMUNOSUPPRESSIVE EFFECT OF EXTRACELLULAR VESICLES FROM PATIENTS WITH MULTIPLE MYELOMA

Author

Hagiwara, Shinya, primary, Ri, Masaki, additional, Asano, Arisa, additional, Masaki, Ayako, additional, Marumo, Yoshiaki, additional, Hirade, Kentaro, additional, Nakashima, Takahiro, additional, Kinoshita, Shiori, additional, Suzuki, Tomotaka, additional, Narita, Tomoko, additional, Komatsu, Hirokazu, additional, and Iida, Shinsuke, additional

Published
2023
Full Text
View/download PDF

11. Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia

Author

Suzuki, Tomotaka, primary, Kusumoto, Shigeru, additional, Kamezaki, Yoshiko, additional, Hashimoto, Hiroya, additional, Nishitarumizu, Nozomi, additional, Nakanishi, Yoko, additional, Kato, Yukiyasu, additional, Kawai, Akimi, additional, Matsunaga, Naohiro, additional, Ebina, Toru, additional, Nakamura, Tomoyuki, additional, Marumo, Yoshiaki, additional, Oiwa, Kana, additional, Kinoshita, Shiori, additional, Narita, Tomoko, additional, Ito, Asahi, additional, Inagaki, Atsushi, additional, Ri, Masaki, additional, Komatsu, Hirokazu, additional, Aritsu, Takashi, additional, and Iida, Shinsuke, additional

Published
2023
Full Text
View/download PDF

12. Case report: Genomic analysis of a therapy-related chronic myelomonocytic leukemia with KMT2A rearrangement that progressed to acute myeloid leukemia with acute promyelocytic leukemia-like features

Author

Suzuki, Tomotaka, primary, Yokomori, Rui, additional, Sanda, Takaomi, additional, Kikuchi, Takaki, additional, Marumo, Yoshiaki, additional, Kinoshita, Shiori, additional, Narita, Tomoko, additional, Masaki, Ayako, additional, Ito, Asahi, additional, Ri, Masaki, additional, Kusumoto, Shigeru, additional, Komatsu, Hirokazu, additional, Inagaki, Hiroshi, additional, and Iida, Shinsuke, additional

Published
2023
Full Text
View/download PDF

14. Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients

Author

Asano, Arisa, primary, Ri, Masaki, additional, Masaki, Ayako, additional, Maeda, Yasuhiro, additional, Tachita, Takuto, additional, Hirade, Kentaro, additional, Marumo, Yoshiaki, additional, Nakashima, Takahiro, additional, Hagiwara, Shinya, additional, Kinoshita, Shiori, additional, Suzuki, Tomotaka, additional, Narita, Tomoko, additional, Kusumoto, Shigeru, additional, Komatsu, Hirokazu, additional, Inagaki, Hiroshi, additional, and Iida, Shinsuke, additional

Published
2022
Full Text
View/download PDF

15. Aberrant tryptophan metabolism leads to unfavorable outcomes in lenalidomide‐treated myeloma patients.

Author

Asano, Arisa, Ri, Masaki, Masaki, Ayako, Maeda, Yasuhiro, Tachita, Takuto, Hirade, Kentaro, Marumo, Yoshiaki, Nakashima, Takahiro, Hagiwara, Shinya, Kinoshita, Shiori, Suzuki, Tomotaka, Narita, Tomoko, Kusumoto, Shigeru, Komatsu, Hirokazu, Inagaki, Hiroshi, and Iida, Shinsuke

Subjects
TRYPTOPHAN, INDOLEAMINE 2,3-dioxygenase, STROMAL cells, MULTIPLE myeloma, T cells, METABOLISM
Abstract

Indoleamine 2,3‐dioxygenase 1 (IDO), an enzyme that metabolizes tryptophan (Trp) to kynurenine (Kyn), is an important microenvironmental factor suppressing antitumor immunity. Here, we investigated the clinical impact of aberrant Trp metabolism in patients with multiple myeloma (MM) treated with lenalidomide (Len) and evaluated its effects on T cell immunity ex vivo. Kyn and Trp concentrations were quantified in sera from 72 patients with relapsed or refractory MM prior to the initiation of therapy with Len plus dexamethasone (Ld). Associations of the Kyn/Trp ratio with progression‐free survival (PFS) and overall survival (OS) were analyzed. The expressions of IDO in tumor and stromal cells were evaluated during co‐culture, and the effects of culture medium containing low Trp and high Kyn concentrations on T cells in the presence of Len were investigated. Patients with high serum Kyn/Trp ratios (≥46.0, n = 22) had significantly shorter PFS and OS than those with low ratios (4.9 vs. 12.6 months, and 15.5 vs. 45.7 months, respectively). MM cells promoted IDO expression in stromal cells during co‐culture in both a direct contact and an indirect manner. Incubation in medium with a high Kyn/Trp ratio significantly inhibited T cell cytokine production and upregulated the expression of inhibitory immune receptors. These effects were sustained even in the presence of Len. In conclusion, a high serum Kyn/Trp ratio is associated with poor prognosis in patients with MM. We propose that aberrant Trp metabolism reduces anti‐tumor immunity and the efficacy of Len therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. P37-7 Investigation of discarded anticancer agents after preparation in Nagoya Memorial Hospital

Author

Hibi, Satoshi, primary, Kabeya, Megumi, additional, Ito, Nobuto, additional, Yuasa, Shu, additional, Shirokawa, Yuko, additional, Nanya, Kengo, additional, Kato, Yuko, additional, Matsunaga, Naohiro, additional, Marumo, Yoshiaki, additional, Yoshida, Takashi, additional, Furuta, Ryuichi, additional, Kataoka, Takae, additional, Kayukawa, Satoshi, additional, and Ina, Kenji, additional

Published
2021
Full Text
View/download PDF

20. Exophiala dermatitidis Fungemia Diagnosed Using Time-of-flight Mass Spectrometry during Chemotherapy for Malignant Lymphoma and Successful Treatment with Voriconazole

Author

Yoshida, Takashi, primary, Tachita, Takuto, additional, Fujinami, Haruna, additional, Oshima, Yoshiko, additional, Sasaki, Hirokazu, additional, Marumo, Yoshiaki, additional, Narita, Tomoko, additional, Ito, Asahi, additional, Ri, Masaki, additional, Kusumoto, Shigeru, additional, Ishida, Takashi, additional, Komatsu, Hirokazu, additional, and Iida, Shinsuke, additional

Published
2019
Full Text
View/download PDF

21. Autoimmune Hemolytic Anemia Obscured by the Obstructive Jaundice Associated with IgG4-related Sclerosing Cholangitis in a Patient with Type 1 Autoimmune Pancreatitis: A Case Report and Review of the Literature

Author

Yoshida, Michihiro, primary, Marumo, Yoshiaki, additional, Naitoh, Itaru, additional, Hayashi, Kazuki, additional, Miyabe, Katsuyuki, additional, Nishi, Yuji, additional, Fujita, Yasuaki, additional, Jinno, Naruomi, additional, Hori, Yasuki, additional, Natsume, Makoto, additional, Kato, Akihisa, additional, Iida, Shinsuke, additional, and Joh, Takashi, additional

Published
2018
Full Text
View/download PDF

26. [Richter syndrome successfully treated with ibrutinib monotherapy: two case reports].

Author

Fujinami H, Kusumoto S, Masaki A, Ohshima Y, Tachita T, Sasaki H, Marumo Y, Yoshida T, Narita T, Ito A, Ri M, Komatsu H, Inagaki H, and Iida S

Subjects
Adenine analogs & derivatives, Humans, Piperidines, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy, Lymphoma, Large B-Cell, Diffuse drug therapy, Pyrazoles therapeutic use, Pyrimidines therapeutic use
Abstract

The Richter syndrome (RS) is defined as a histologically diagnosed diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma. A standard treatment for RS has not yet been established. Most patients with RS are treated with combination chemotherapy regimens used for de novo DLBCL or HL. Recently, the Bruton's tyrosine kinase inhibitor, ibrutinib (IBR), has shown remarkable efficacy in CLL; however, limited evidence exists regarding its single agent efficacy in RS. We encountered two patients with RS in whom CLL transformed to DLBCL, confirmed by G-banding/spectral karyotyping analysis. Both patients achieved durable responses for 12 and 10 months, with IBR alone. Hemorrhagic cystitis due to adenovirus occurred in one patient at an initial dose of 420 mg/day, but a dose reduction to 280 mg/day made long-term continuation of IBR possible. Interestingly, retreatment with IBR alone achieved disease control again for 5.5 and 2 months, after these patients underwent salvage chemotherapies for aggressive relapse.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results